{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"CheckMate 331","nct_id":"NCT02481830","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-331-nct02481830. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CheckMate331","arms":[{"description":"Nivolumab intravenous infusion as specified","label":"Arm A Nivolumab","type":"EXPERIMENTAL"},{"description":"Topotecan as specified","label":"Arm B Chemotherapy Topotecan","type":"ACTIVE_COMPARATOR"},{"description":"Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)","label":"Arm B Chemotherapy Amrubicin","type":"ACTIVE_COMPARATOR"}],"collaborators":["Ono Pharmaceutical Co., Ltd."],"completion_date":{"date":"2022-08-30","type":"ACTUAL"},"conditions":["Lung Cancer"],"enrollment":{"count":569,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"},{"name":"Amrubicin","otherNames":[],"type":"DRUG"}],"last_update":"2023-07-27","lead_sponsor":"Bristol-Myers Squibb","official_title":"An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2018-08-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"OS was followed continuously while participants were on the study drug and every 3 months, minimum follow up for overall survival was 15.8 months"}],"references":[],"start_date":{"date":"2015-09-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT02481830"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-331-nct02481830"}